Cagrilintide
Cagrilintide is a long-acting amylin analogue, a once-weekly injection that mimics a natural fullness hormone to curb appetite and reduce body weight. It is studied both on its own and combined with semaglutide as CagriSema, which produced about 20 percent weight loss in late-stage trials. It is investigational and not yet approved.
Verified sources for Cagrilintide
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Cagrilintide
A once-weekly injection that copies amylin, a hormone the pancreas releases after meals to signal fullness, so people feel satisfied sooner and eat less.
Mimics amylin, a natural hormone released alongside insulin after eating. Amylin acts on the parts of the brain that control hunger, increasing the sense of fullness so meals end sooner and between-meal hunger drops.
Because it is long-acting, a single weekly dose keeps this fullness signal switched on across the whole week.
Slows the rate at which the stomach empties, so food stays in the stomach longer and the feeling of fullness lasts.
Amylin and GLP-1 are two separate fullness signals that the body uses together. Cagrilintide supplies the amylin signal and semaglutide supplies the GLP-1 signal.
Pairing the two as CagriSema produced greater weight loss in trials than either medicine on its own, reaching about 20 percent of body weight over 68 weeks.
On its own, weekly cagrilintide reduced body weight in a dose-dependent way, up to about 11 percent over 26 weeks in mid-stage research, outperforming an older daily weight-loss injection.
Side effects were mostly stomach-related, such as nausea, and were generally temporary and mild to moderate.
Read Full Cagrilintide Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss